908 Devices (MASS) 16th Annual East Coast IDEAS Conference summary

Strategic transformation and focus

• Underwent a major transformation, divesting the desktop bioprocessing portfolio in 2025 to focus on handheld chemical detection for public health, safety, and defense markets.

• Launched "908 Devices 2.0" with sharper operational alignment, improved financials, and a more focused product strategy.

• Achieved 18% year-over-year revenue growth in 2025 and positive adjusted EBITDA in Q4 2025.

• Diversified customer base, reducing reliance on large federal contracts and increasing state, local, and international sales.

• Ended Q1 2026 with $112 million in cash, no debt, and a growing installed base of nearly 3,900 devices in over 70 countries.

Product innovation and portfolio expansion

• Expanded from a single product to a comprehensive portfolio including MX908 (mass spec), XplorIR, VipIR (FTIR/Raman), ProtectIR, ThreatID, and the newly acquired NIRLAB.

• NIRLAB acquisition adds a cloud-connected, subscription-based device for frontline law enforcement, with over 100 global customers and high recurring revenue.

• Devices now cover rapid screening, trace detection, and broad-spectrum analysis, all integrated with cloud-based data and software platforms.

• Product life cycles are typically 5-10 years, with ongoing development of next-generation devices to drive replacement cycles.

• Integration with drones, UGVs, and robotics is underway, expanding field deployment opportunities.

Market drivers and customer impact

• Addressing urgent threats such as the opioid crisis, toxic industrial materials, and rising global defense needs.

• Real-world impact demonstrated by programs like Virginia's Operation FREE, which reduced correctional facility overdoses to zero using MX908.

• State and local customers now represent about 50% of revenues, providing stable, predictable demand.

• Legislative and funding tailwinds include increased DHS grants, NATO defense spending, and U.S. Honor Act recognition of firefighter cancer risks.

• Shift away from unreliable field tests is driving demand for advanced electronic detection solutions.